VA Committee Zooms In on Veteran Readjustment Plans
Published Date: 1/21/2026
Notice
Summary
The Advisory Committee on the Readjustment of Veterans will meet online on March 24, 2026, to review their latest report and plan future meetings. This group helps the VA improve benefits and services for Veterans adjusting to civilian life, especially those who served in combat. The public can join, share comments, and help shape how Veterans get support—no money changes announced, but your voice matters!
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2025-21242 — Extending Deadline for Debtor To Request a Waiver
The VA is giving veterans more time—up to one year instead of 180 days—to ask for a waiver on debts related to benefits. This change, effective January 26, 2026, helps reduce stress by giving veterans extra breathing room to handle their debt issues. It doesn’t cost veterans extra money but makes the process friendlier and fairer.
2025-18827 — Extension of Program of Comprehensive Assistance for Family Caregivers Eligibility for Legacy Participants and Legacy Applicants
The VA is giving family caregivers of veterans more time to stay in their special support program by extending the deadline from 2025 to 2028. This means caregivers and veterans who joined the program earlier (the legacy group) can keep getting help for three more years. No changes to money or benefits, just extra time to enjoy the support they deserve!
2025-14687 — Reproductive Health Services
The VA is planning to stop covering abortions and abortion counseling again, reversing a 2022 change. This affects veterans and their families who use VA and CHAMPVA health benefits. The change aims to focus VA services on what they consider essential care, with no new costs or timing details shared yet.
2026-11752 — Grants for the Rural Veterans Coordination Pilot; Rescission
The VA is officially ending the Rural Veterans Coordination Pilot grant program because its legal permission has expired. This means no new grants will be given, and the rules about this program are being removed to keep things clear and simple. The change takes effect on July 13, 2026, so rural veterans and community groups should note the program is officially closed.
2026-11766 — Privacy Act of 1974; System of Records
The Department of Veterans Affairs is updating its records system that helps investigate crimes involving veterans. These changes improve how information is stored, accessed, and kept safe. If you want to share your thoughts, you have 30 days from June 11, 2026, to comment before the new rules take effect.
2026-11494 — Agency Information Collection Activity: Application for Authority To Close Loans on an Automatic Basis Nonsupervised Lenders
The VA is updating how nonsupervised lenders apply to automatically close loans and recognize agents, moving the process online. This change affects lenders who want quicker loan approvals and yearly recertifications, with more people expected to apply. Comments on this update are open until July 9, 2026, and the paperwork burden will nearly double due to more applicants.
Previous / Next Documents
Previous: 2026-01065 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; KYGEVVI (Doxecitine and Doxribtimine)
The FDA just gave a special fast-track ticket called a Priority Review Voucher to UCB, Inc. for their rare pediatric disease drug KYGEVVI, approved in November 2025. This voucher helps speed up future drug reviews, saving time and potentially money for the company. It’s a big win for patients with thymidine kinase 2 deficiency and a boost for UCB’s innovation efforts.
Next: 2026-01068 — Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints To Support Accelerated Approval; Draft Guidance for Industry; Availability
The FDA is rolling out new draft guidance to help drug makers use special tests called minimal residual disease (MRD) and complete response (CR) to speed up approval of multiple myeloma treatments. This means patients with this blood cancer could get access to promising drugs faster. Industry folks should send their feedback by March 23, 2026, so the FDA can finalize the rules and keep innovation moving without unnecessary delays.